NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study.

doi:10.1002/1878-0261.13542

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study.

Molecular oncology - 1 Feb 2024

Ikeda Satoshi, Tsuboi Masahiro, Sakai Kazuko, Misumi Toshihiro, Akamatsu Hiroaki, Shoda Hiroyasu, Sakakura Noriaki, Nakamura Atsushi, Ohde Yasuhisa, Hayashi Hidetoshi, Okishio Kyoichi, Okada Morihito, Yoshino Ichiro, Okami Jiro, Takahashi Kazuhisa, Ikeda Norihiko, Tanahashi Masayuki, Tambo Yuichi, Saito Haruhiro, Toyooka Shinichi, Inokawa Hidetoshi, Chen-Yoshikawa Toyofumi, Yokoyama Toshihide, Okamoto Tatsuro, Yanagitani Noriko, Oki Masahide, Takahama Makoto, Sawa Kenji, Tada Hirohito, Nakagawa Kazuhiko, Mitsudomi Tetsuya, Nishio Kazuto

Abstract excerpt

The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Although the primary endpoint of disease-free survival (DFS) was not met, we searched for molecular predictors of adjuvant gefitinib efficacy. Of 234 patients enrolled in the IMPACT study, 202...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CREB-Binding Protein

Share to Cyclic AMP Response Element-Binding Protein

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Receptor, Notch1

Share to Translational Research, Biomedical

Share to Vinorelbine

Source

Open in PubMed Open full text

Identifiers

PMID: 37864465
DOI: 10.1002/1878-0261.13542
PMCID: PMC10850799

Genes

NOTCH1
CREBBP
EGFR
IMPACT
CSMD3
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study.PMID 37864465Read ↗

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).Semantic proximity Read ↗

Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II-III NSCLC With Distinct Adjuvant Therapy OutcomesSemantic proximity Read ↗

Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.Semantic proximity Read ↗

Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.Semantic proximity Read ↗

EGFR and PI3K Pathway Activities Might Guide Drug Repurposing in HPV-Negative Head and Neck CancersSemantic proximity Read ↗

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.Semantic proximity Read ↗

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.Semantic proximity Read ↗

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.Semantic proximity Read ↗

Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survivalSemantic proximity Read ↗

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.Semantic proximity Read ↗

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.